Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients
H.J. Boyle, Shabbir M.H. Alibhai, Lore Decoster, et al.
European Journal of Cancer (2019) Vol. 116, pp. 116-136
Open Access | Times Cited: 184

Showing 1-25 of 184 citing articles:

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet, Roderick C.N. van den Bergh, Erik Briers, et al.
European Urology (2020) Vol. 79, Iss. 2, pp. 243-262
Closed Access | Times Cited: 2285
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al.
European Urology (2024) Vol. 86, Iss. 2, pp. 148-163
Closed Access | Times Cited: 266
Epidemiology and genomics of prostate cancer in Asian men
Yao Zhu, Miao Mo, Wei Yu, et al.
Nature Reviews Urology (2021) Vol. 18, Iss. 5, pp. 282-301
Closed Access | Times Cited: 186
Is cancer biology different in older patients?
Yannick Van Herck, Annelies Feyaerts, Shabbir M.H. Alibhai, et al.
The Lancet Healthy Longevity (2021) Vol. 2, Iss. 10, pp. e663-e677
Open Access | Times Cited: 107
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Silke Gillessen, Alberto Bossi, Ian D. Davis, et al.
European Journal of Cancer (2023) Vol. 185, pp. 178-215
Open Access | Times Cited: 101
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Karim Fizazi, Arun Azad, Nobuaki Matsubara, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 257-264
Open Access | Times Cited: 61
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Karim Fizazi, Ken Herrmann, Bernd J. Krause, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 6, pp. 597-610
Open Access | Times Cited: 53
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Silke Gillessen, Fabio Turco, Ian D. Davis, et al.
European Urology (2024)
Open Access | Times Cited: 16
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Nobuaki Matsubara, Arun Azad, Neeraj Agarwal, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 4, pp. 470-480
Closed Access | Times Cited: 2
Metastatic Prostate Cancer: Treatment Options
Vérane Achard, Paul Martin Putora, Aurelius Omlin, et al.
Oncology (2021) Vol. 100, Iss. 1, pp. 48-59
Closed Access | Times Cited: 102
Older adults with cancer and their caregivers — current landscape and future directions for clinical care
Sindhuja Kadambi, Kah Poh Loh, Richard F. Dunne, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 12, pp. 742-755
Open Access | Times Cited: 98
Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play
Girijesh Kumar Patel, Natasha Chugh, Manisha Tripathi
Cancers (2019) Vol. 11, Iss. 10, pp. 1405-1405
Open Access | Times Cited: 97
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes
Maha Hussain, Karim Fizazi, Neal D. Shore, et al.
JAMA Oncology (2024) Vol. 10, Iss. 6, pp. 807-807
Closed Access | Times Cited: 13
Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes
Amin Ullah, Yongxiu Chen, Rajeev K. Singla, et al.
Pharmacological Research (2024) Vol. 204, pp. 107213-107213
Open Access | Times Cited: 11
Extracellular vesicle mimics made from iPS cell-derived mesenchymal stem cells improve the treatment of metastatic prostate cancer
Qingguo Zhao, Bo Hai, Jack Kelly, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 46
Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic review
Riccardo Campi, Alessandro Berni, Daniele Amparore, et al.
Minerva Urology and Nephrology (2021) Vol. 74, Iss. 2
Closed Access | Times Cited: 45
The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis
Reza Sari Motlagh, Fahad Quhal, Keiichiro Mori, et al.
The Journal of Urology (2020) Vol. 205, Iss. 1, pp. 60-67
Closed Access | Times Cited: 43
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis
Chiara Ciccarese, Roberto Iacovelli, Cora N. Sternberg, et al.
European Journal of Cancer (2022) Vol. 173, pp. 276-284
Closed Access | Times Cited: 26
TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer (TOPCOP3): A pilot randomized controlled trial and process evaluation
Shabbir M.H. Alibhai, Martine Puts, Rana Jin, et al.
Journal of Geriatric Oncology (2024) Vol. 15, Iss. 6, pp. 101750-101750
Open Access | Times Cited: 5
Embracing the complexity: Older adults with cancer-related cognitive decline—A Young International Society of Geriatric Oncology position paper
Mackenzi Pergolotti, Nicolò Matteo Luca Battisti, Lynne Padgett, et al.
Journal of Geriatric Oncology (2019) Vol. 11, Iss. 2, pp. 237-243
Open Access | Times Cited: 39
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen‐receptor–targeted therapy for metastatic castration‐resistant prostate cancer
Shabbir M.H. Alibhai, Henriette Breunis, Aaron R. Hansen, et al.
Cancer (2021) Vol. 127, Iss. 14, pp. 2587-2594
Open Access | Times Cited: 27
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer
Stéphane Oudard, Raffaele Ratta, Éric Voog, et al.
JAMA Oncology (2023) Vol. 9, Iss. 12, pp. 1629-1629
Closed Access | Times Cited: 11
Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology
Anupam Batra, Daniel Glick, Mario J. Valdés
Current Oncology (2024) Vol. 31, Iss. 2, pp. 1047-1062
Open Access | Times Cited: 4
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial
Xuyu Zhang, Feng Zhou, Tong Lu, et al.
World Journal of Urology (2025) Vol. 43, Iss. 1
Closed Access
Frailty and gynecologic cancer: A cross-sectional analysis of the Canadian Longitudinal Study on Aging
Melissa Lavecchia, Maura Marcucci, Parminder Raina, et al.
International Journal of Gynecological Cancer (2025), pp. 101642-101642
Closed Access
Page 1 - Next Page

Scroll to top